RxDoctor Payments Data

Marilou Tablang-Jimenez, MD

Psychiatry · Germantown, MDNPI 1811040355

Payments from drug & device makers

$4,968in general payments, 2019–2025

Across 93 payments — averaging $53.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$2K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$848
  • Sunovion Pharmaceuticals Inc.$664
  • AbbVie$530
  • Alkermes, Inc.$507
  • Neurocrine Biosciences, Inc.$164
  • plus $692 from 9 others

What the payments were for

  • Food & beverage$4,90999%
  • Education$591%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,968 in reported general payments places this provider in the 90th percentile of 851 psychiatry providers in Maryland.

See all psychiatry providers in Maryland

Medicare billing

Part B allowed, 2024
$31,349
Medicare patients
37
Services billed
297

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Abilify MaintenaAripiprazole23$65,158
Lurasidone Hcl17$5,318
Lisdexamfetamine Dimesylate14$2,588
Aripiprazole40$1,475
Gabapentin30$714
Hydroxyzine Hcl17$612
Olanzapine14$594
Quetiapine Fumarate34$507
Benztropine Mesylate37$436
Duloxetine Hcl26$425
Bupropion XlBupropion Hcl11$313
Mirtazapine16$277
Lamotrigine15$263
Eszopiclone12$226
Trazodone Hcl30$206

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Abilify Maintena$1,562$65,15823 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 851 psychiatry providers in Maryland.

Other psychiatry in Germantown

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →